IL-38 Evaluation as a Biomarker in Pediatric Asthma

The aim of this study is to investigate the associations between serum IL-38 levels and different variables of asthma in children such as laboratory variables, pulmonary function test results, the diagnosis of asthma, and in correlation with disease severity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bronchial Asthma Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

6 year–14 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Asmaa Kamal

Cairo, 11562, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients fulfilled the criteria of the Global Initiative for Asthma (GINA)
Age group:6-14 years

Exclusion criteria

Malignancy
Chronic inflammatory diseases

Treatment and study plan

Il-38 serum level

Diagnostic Test

measurement of serum levels of IL-38

Primary outcomes

serum IL-38 levels

Time frame: within 6 months

Measurement of Interleukin 38 in sera of all study subjects by ELISA

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Serum Human IL-38 Levels in Asthmatic Children

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: May 9, 2022
Registry last updated: May 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed